MedTrace Logo

Cognition in Older Adults With Cancer Receiving Systemic Anti-Cancer Therapy

NCT07411105 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2026-02-27

No results posted yet for this study

Summary

The majority of cancer diagnoses occur in adults age 65 years and over. This population is also rapidly expanding. There is a growing need for increased understanding about the potential impact of various newer therapies on common geriatric impairments in this group.

The aim of this study is to examine how feasible it is to carry out a study of cognitive function in older adults (age 65+) who are newly commencing anti-cancer treatments, specifically 'immune checkpoint inhibitor' therapy, over time. Participants in the study undergo four tests of memory and concentration every six weeks for a six month period. Additionally, the researcher will gather information about the participants' non-cancer therapy medications, physical and psychological symptoms, day to day functioning and any changes to these factors over time.

The purpose of the study is to examine a) recruitment, retention and engagement of participants to study procedures; b) to gather preliminary information about cognitive function in older adults commencing immune checkpoint inhibitor treatments and potential associations with cognitive decline over time.

Conditions

  • Cancer
  • Older Adults (65 Years and Older)
  • Cognition

Sponsors & Collaborators

  • University of Dublin, Trinity College

    collaborator OTHER

  • St. James's Hospital, Ireland

    collaborator OTHER

  • St Vincent's University Hospital, Ireland

    collaborator OTHER

  • Our Lady's Hospice and Care Services

    lead OTHER

Principal Investigators

  • Andrew Davies, MBBS MSc MD · Our Lady's Hospice and Care Services

  • Amanda Lavan, MB, BCh, BAO, FRCPI, BSc, MSc · Mercer's Institute for Successful Ageing, St. James's Hospital, Dublin 8

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-21
Primary Completion
2026-05-31
Completion
2026-07-31

Countries

  • Ireland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07411105 on ClinicalTrials.gov